N-terminal probrain natriuretic peptide as a biomarker of cardioembolic stroke

International Journal of Stroke

Volumn 6, Issue 5, 2011, Pages 398-403

  Fonseca, Ana Catarina ^a   Matias, Joaquim Sampaio ^b   Pinho e Melo, Teresa ^a   Falcão, Filipa ^a   Canhão, Patrícia ^a   Ferro, José M ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Atrial fibrillation; Biomarker; Cardioembolic; Ischemic stroke; NT proBNP; Stroke

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CHEMOLUMINESCENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AGED; AREA UNDER CURVE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; HEART DISEASES; HUMANS; INTRACRANIAL EMBOLISM; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 80053183290     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00606.x     Document Type: Article

References (31)

1. Schneider AT, Kissela B, Woo D et al. Ischemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke 2004; 35:1552-6.
2. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001; 32:2735-40.
3. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 2007; 38:2935-40.
4. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35:1647-51.
5. Wallmann D, Tüller D, Wustmann K et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke 2007; 38:2292-4.
6. Tayal AH, Tian M, Kelly KM et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 2008; 71:1696-701.
7. Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36:1115-9.
8. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-62.
9. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
10. Minamino N, Aburaya M, Ueda S, Kangawa K, Matsuo H. The presence of brain natriuretic peptide of 12, 00 daltons in porcine heart. Biochem Biophys Res Commun 1988; 155:740-6.
11. Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 2005; 36:270-5.
12. Giannakoulas G, Hatzitolios A, Karvounis H et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 2005; 56:723-30.
13. Mäkikallio AM, Mäkikallio TH, Korpelainen JT et al. Natriuretic peptides and mortality after stroke. Stroke 2005; 36:1016-20.
14. Nakagawa K, Yamaguchi T, Seida M et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005; 19:157-64.
15. Montaner J, Perea-Gainza M, Delgado P et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39:2280-7.
16. Wozakowska-Kaplon B, Opolski G, Herman Z, Kosior D. Natriuretic peptides in patients with atrial fibrillation. Cardiol J 2008; 15:525-9.
17. Iltumur K, Yavavli A, Apak I, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J 2006; 151:1115-22.
18. Naya T, Yukiiri K, Hosomi N et al. Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation. Cerebrovasc Dis 2008; 26:434-40.
19. Tomita H, Metoki N, Saitoh G et al. Elevated plasma brain natriuretic peptide levels independent of heart disease in acute ischemic stroke: correlation with stroke severity. Hypertens Res 2008; 31:1695-702.
20. Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24:35-41.
21. Pexman JH, Barber PA, Hill MD et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. Am J Neuroradiol 2001; 22:1534-42.
22. Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta 2006; 369:95-9.
23. Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal proBNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95:948-54.
24. Shibazaki K, Kimura K, Iguchi Y, Okada Y, Inoue T. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med 2009; 48:259-64.
25. Ferro JM. Patterns of ischemic cerebral disease. J Neurol 2004; 25:1-10.
26. Okada Y, Shibazaki K, Kimura K, Iguchi Y, Miki T. Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischemic stroke and transient ischaemic attack. Eur J Neurol 2010; 17:326-31.
27. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625.
28. Berthet K, Lavergne T, Cohen A et al. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 2000; 31:398-403.
29. Ferro J, Melo T, Oliveira V, Crespo M, Canhão P, Pinto A. An analysis of the admission delay of acute stroke. Cerebrovasc Dis 1994; 4:72-5.
30. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clincal use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999; 134:437-44.
31. Jensen JK, Mickley H, Bak S, Korsholm L, Kristensen SR. Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke. Cerebrovasc Dis 2006; 22:439-44.